Lawsuits Seek to Block Theravance's $17/Share Sale to Zymeworks
TBPH sits 30% above its 52-week low of $13.08 on light trading volume (0.1× avg).
Summary
Multiple lawsuits have been filed seeking to block Theravance's acquisition by Zymeworks at $17.00 per share in cash. The suits introduce legal uncertainty that could delay or derail the deal, which was announced in June. Theravance reported a Q2 net loss of $5.9 million, an improvement from the prior year, but the litigation now becomes the key risk to closing. Zymeworks (ZYME) is the acquirer and also faces potential disruption to its strategic plans.
At the time of this announcement, TBPH was trading at $17.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $884.4M. The 52-week trading range was $13.08 to $21.03. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.